<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9218106A-E8CE-46A5-AABC-B4C8ED148690"><gtr:id>9218106A-E8CE-46A5-AABC-B4C8ED148690</gtr:id><gtr:name>University of Amsterdam</gtr:name><gtr:address><gtr:line1>Liaison Office</gtr:line1><gtr:line2>PO Box 19268</gtr:line2><gtr:line4>Amsterdam</gtr:line4><gtr:line5>Amsterdam</gtr:line5><gtr:postCode>1000 GG</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Health Service and Population Research</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9218106A-E8CE-46A5-AABC-B4C8ED148690"><gtr:id>9218106A-E8CE-46A5-AABC-B4C8ED148690</gtr:id><gtr:name>University of Amsterdam</gtr:name><gtr:address><gtr:line1>Liaison Office</gtr:line1><gtr:line2>PO Box 19268</gtr:line2><gtr:line4>Amsterdam</gtr:line4><gtr:line5>Amsterdam</gtr:line5><gtr:postCode>1000 GG</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4AF39F62-1820-411D-BFB5-E5107F62AB4D"><gtr:id>4AF39F62-1820-411D-BFB5-E5107F62AB4D</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>Derek</gtr:otherNames><gtr:surname>Hayes</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ01219X%2F1"><gtr:id>B85D29A0-3469-49FE-B3C3-0767C80A5CF2</gtr:id><gtr:title>Risks, benefits and NHS costs associated with antipsychotic medications prescribed to individuals diagnosed with serious mental illness</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/J01219X/1</gtr:grantReference><gtr:abstractText>The proposed research is relevant to people experiencing serious mental illnesses (SMI) including schizophrenia, schizoaffective disorder and bipolar affective disorder. SMIs are mental disorders which have a substantial impact on people's lives. Those with SMIs are at increased risk of suicide, accidents, violence, heart disease and stroke. The impact of SMIs on life expectancy is substantial and generally higher than that of smoking, diabetes and obesity. Our research has estimated that individuals with SMI die between 10-15 years earlier than the general population. However, reasons for this remain unclear. 

Despite improving healthcare, people with SMIs continue to have frequent relapses and reduced ability to function. Antipsychotic medications, a mainstay of treatment for SMIs, are used to manage psychotic symptoms, including hallucinations, delusions and disturbed thoughts. The effectiveness of antipsychotic medications has been assessed in numerous experimental clinical trials; however, a number of adverse effects have been reported, including, diabetes, lowered white blood cell count and heart disease. Also experimental clinical trials are performed under ideal conditions and over relatively short time periods. In practice, antipsychotics are used in a variety of ways that differ from how they are tested in trials. For example, often more than one antipsychotic is prescribed or clinicians may switch medications or increase the dose in an effort to maximise the benefit. Currently, there is very limited information on the risks and benefits of these decisions in real-life clinical settings. 

Detailed electronic patient records provide an ideal source of data to investigate the risks and benefits associated with antipsychotic medication use in real-life. The South London and Maudsley NHS Foundation Trust (SLAM) provides all mental healthcare to 4 London boroughs and is the largest such provider in Europe. Electronic clinical records have been used across all SLAM services since 2006, and the Clinical Record Interactive Search (CRIS) system allows researchers to search and retrieve anonymised information from the records efficiently. There are currently over 180,000 cases in the CRIS system providing in-depth information which I have used in previous investigations.

Aims: My aim is to investigate antipsychotic profiles (antipsychotic use over time) and examine the impact of these profiles on the mental health, physical health and risk of mortality in people with SMIs. This will be achieved using CRIS linked to routine mortality tracing and death certificates, routine hospital care information and a local General Practice dataset making it possible to assess primary, emergency and acute care, causes of mortality, physical and mental health outcomes and associated costs for a large group of SLAM patients with SMIs. 

Impact: This research will improve our understanding of the physical and mental health consequences of antipsychotic medications and the ways in which they are used in secondary care. This information would prove invaluable for clinical practice allowing clinicians to make better informed decisions regarding the risks and benefits of commonly used medications. Understanding associated risks, benefits, service use and costs can inform healthcare policy, allow health service providers to make more effective use of available resources and assist the NHS in providing the highest level of patient care. 

Researchers: As the fellowship applicant, I will coordinate the study activities in this multidisciplinary team under the supervision of Dr Robert Stewart, and mentored by Professor Matthew Hotopf at Kings Collage London, Institute of Psychiatry. The collaborators will contribute expertise and guidance in their respective fields.</gtr:abstractText><gtr:technicalSummary>Part 1: I will model cross-sectional and longitudinal antipsychotic medication profiles to identify prescribing patterns exploring polypharmacy, medication switching, antipsychotic load and antipsychotic action ( based on known target receptors). I will explore associations between antipsychotic profiles and cause-specific mortality in people with SMI. Text mining algorithms and structured fields in CRIS will provide data on antipsychotics and potential confounders making it possible to control for confounders including disease severity (using HONOS and level of mental health service contact) and other medications. Routine mortality tracing already provides data on deaths, and cause of death will be retrieved by the Medical Research Information Service.
Part 2: I will investigate associations between cross-sectional/longitudinal antipsychotic medication profiles (identified in part 1) and physical illness in people with SMI. CRIS will provide data on use of mental health services, psychotropic medications and mental health outcomes. A linkage between CRIS and Hospital Episode Statistics (HES), will provide data on emergency and acute hospital care, diagnosis and length of stay for physical illness in those with SMIs and control for potential confounders including disease profile/management and pre-existing illness. In addition, in a subsample of SMI cases I will examine primary care outcomes through a link between CRIS and Lambeth DataNet, a primary care database for one of four SLAM catchment boroughs.
Part 3: Using the CRIS to HES and Lambeth DataNet linkage, I will calculate costs associated with different antipsychotic medication profiles, allocating costs to admissions and medications prescribed while in contact with SLAM services as well as costs associated with acute and emergency hospital care. Benefit will be estimated with longitudinal observational data in nested studies comparing good and poor disorder control under different pharmacotherapy profiles.</gtr:technicalSummary><gtr:potentialImpactText>This fellowship proposal is relevant to people with serious mental illnesses (SMIs) including schizophrenia, schizoaffective disorder and bipolar affective disorder and the clinicians who treat them. Despite medical advancements SMIs continue to be associated with a chronic relapsing course and notable health disparities including a substantially reduced life expectancy. In real-life clinical settings antipsychotic medications designed to treat SMIs are used in a variety of ways that go beyond the scope of most randomised controlled trials. Additional information is required to understand fully the potential consequences of antipsychotic pharmacotherapy in real-life settings. This information is essential to improving outcomes for people with SMIs. In this fellowship proposal I will draw on electronic secondary mental health care records linked to mortality tracing and primary, emergency and acute care databases to examine the impact of antipsychotic prescribing practices and medication profiles on mental health, physical health and risk of mortality in people with SMIs. This information would allow clinicians to make more informed decisions based on a clear understanding of risks and benefits of antipsychotic prescribing practices for improved patient outcomes. As the planned research progresses clinicians will be able to access this information from a variety of sources including presentations at scientific conferences, open access peer-reviewed journals and on the BRC-MH website where results summaries will be featured. Much attention has been paid to service user involvement in the work undertaken at the SLAM BRC-MH including the setting up of a Stakeholder Participation Theme. In addition there is an ongoing programme set up to publicize our research to staff and service users in SLAM and neighbouring Trusts. These efforts are carried out in conjunction with the IoP media support unit and the BRC-MH Stakeholder Participation Theme.

The proposed research aims increase our understanding the risks, benefits and costs of current prescribing practices which can inform healthcare policy and treatment guidelines. Timescales for this type of impact are likely to be relatively rapid, within say 5-10 years of the output, although may depend on the availability of confirmatory findings from other samples. Because of the observational nature of the data (as distinct from randomized controlled trial data) findings and evidence will be contributory rather than definitive, but the objective will be a more evidence-based approach to medication use in the disorders of interest. As well as assessment of mental and physical health consequences of prescribing practices this proposal includes a health economics component where costs will be attributed to medications and primary, emergency, acute and mental health care service use. This information will allow health service providers to make more effective use of available resources and assist the NHS in providing the highest level of patient care, again with a similar timescale. Result summaries will be fed back to relevant organizations such as NICE with the aim of directly impacting NHS policy and current patient care.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>354548</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Amsterdam</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Prof Lieuwe de Haan AMC University of Amsterdam</gtr:description><gtr:id>64334BBC-703A-4445-B6FF-D5B77012CBFE</gtr:id><gtr:impact>Established agreement to undertake this work. Work has initiated on Natural Language Processing algorithm for extracting obsessive compulsive symptoms.</gtr:impact><gtr:outcomeId>hdfxBuq6uot-1</gtr:outcomeId><gtr:partnerContribution>Professor Lieuwe de Haan will contribute his expertise on obsessive compulsive symptoms and contribute to research design and publications</gtr:partnerContribution><gtr:piContribution>We will look at the impact of anti-psychotic medications on obsessive compulsive symptoms in people with serious mental illness. We provide CRIS data to answer these as well as expertise in extracting/analyzing with these data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>NLP for antipsychotic polypharmacy, Ulm, Germany</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>ED8CF1B8-16D5-4A66-9451-01239C4A1FB0</gtr:id><gtr:impact>Talk sparked questions and discussion afterwards

Raised awareness of this research with an international audience</gtr:impact><gtr:outcomeId>5628b5787c1c96.69608656</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Clozapine ENMESH Malalga, Spain</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2501C18B-8C06-48DE-9CE0-046D84D75FF4</gtr:id><gtr:impact>Talk sparked questions and discussion afterwards

Raised awareness of this research internationally</gtr:impact><gtr:outcomeId>5628afaa2b35f9.36212777</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Predictors of Polypharmacy IFPE Bergen, Norway</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AA23E746-0B5F-488D-9D49-C6648283D061</gtr:id><gtr:impact>Talk sparked questions and discussion afterwards

Raised awareness of this research nternationally</gtr:impact><gtr:outcomeId>5628ab3eead573.98536643</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Clozapine-EPA Ulm Germany</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FE6DB4E8-0D21-4011-98A0-045EA22B25F0</gtr:id><gtr:impact>Talk sparked questions and discussion afterwards

Raised awareness of this research with an international audience</gtr:impact><gtr:outcomeId>5628b3d8282943.82996648</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Predictors of Polypharmacy ENMESH Malaga, Spain</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CE2250C5-9AC1-4A30-997C-8373C839BD92</gtr:id><gtr:impact>Talk sparked questions and discussion afterwards

Raised awareness of this research in an international audience</gtr:impact><gtr:outcomeId>5628b2592370a0.82327783</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Clozapine IFPE Bergen Norway</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BB774BC0-C306-4DA8-9271-C68469AF693A</gtr:id><gtr:impact>Talk sparked questions and discussions

Raised awareness of this research internationally</gtr:impact><gtr:outcomeId>5627ea04cb01f8.88313230</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>My research involves the use of an anonymized electronic health records of psychiatric patients - CRIS database- which includes all patient records for more than 230,000 patients. Much of the most useful information is in the free text fields (involving billions of words) so not practical for coding by hand. I have led the development of natural language processing applications for extracting pharmacotherapy data. These NLP applications take into account the linguistic context automatically extracting/coding designated aspects of the free text. I have refined and improved these applications during my fellowship to make them more useful for research. Other researchers can access the CRIS database and use these technologies but they need to gain oversite committee approval before they do so.</gtr:description><gtr:id>47EE3522-97A3-4E14-9046-849C29F9B802</gtr:id><gtr:impact>This NLP application has made it possible to extract and use medications data on a large scale from anonymized mental health records. This has made a number of areas of research possible for researchers using the CRIS database including: determining predictors of anti psychotics prescribing in children; investigating the impact of certain anti-psychotics on cause specific mortality; determining predictors of anti psychotic poly-pharmacy prescribing.</gtr:impact><gtr:outcomeId>546673287897e6.66266607</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Pharmacotherapy NLP data extraction</gtr:title><gtr:type>Computer model/algorithm</gtr:type><gtr:url>http://brc.slam.nhs.uk/about/core-facilities/cris</gtr:url><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>9902D28C-C6B9-4FE6-A246-36733FD9E7C9</gtr:id><gtr:title>The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders.</gtr:title><gtr:parentPublicationTitle>Schizophrenia bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7c1fd0a0b46242cebcced6e3015aa64"><gtr:id>f7c1fd0a0b46242cebcced6e3015aa64</gtr:id><gtr:otherNames>Hayes RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0586-7614</gtr:issn><gtr:outcomeId>561e089b9f8ab1.80714468</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5F3D639-E8D9-4F90-9EBF-008FF1F70A89</gtr:id><gtr:title>Abuse and other correlates of common mental disorders in youth: a cross-sectional study in Goa, India.</gtr:title><gtr:parentPublicationTitle>Social psychiatry and psychiatric epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b0c5b13844d147cd849b3727402d8ed"><gtr:id>7b0c5b13844d147cd849b3727402d8ed</gtr:id><gtr:otherNames>Fernandes AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0933-7954</gtr:issn><gtr:outcomeId>pm_23439_29_23111769</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C40C25D-E2F9-4E39-B161-1FEE7820058A</gtr:id><gtr:title>Development and evaluation of a de-identification procedure for a case register sourced from mental health electronic records.</gtr:title><gtr:parentPublicationTitle>BMC medical informatics and decision making</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b0c5b13844d147cd849b3727402d8ed"><gtr:id>7b0c5b13844d147cd849b3727402d8ed</gtr:id><gtr:otherNames>Fernandes AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1472-6947</gtr:issn><gtr:outcomeId>pm_23439_29_23842533</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2B0C6FA-585F-4828-A2D3-5E098504FB65</gtr:id><gtr:title>Negative Symptoms in Early-Onset Psychosis and Their Association With Antipsychotic Treatment Failure.</gtr:title><gtr:parentPublicationTitle>Schizophrenia bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb90a833dbe37ce12de107ab7a5f2964"><gtr:id>eb90a833dbe37ce12de107ab7a5f2964</gtr:id><gtr:otherNames>Downs J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0586-7614</gtr:issn><gtr:outcomeId>5aaba382a91ff9.95056952</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25442C4B-1096-4687-8088-5FBEF0036798</gtr:id><gtr:title>Associations between risk of mortality and atypical antipsychotic use in vascular dementia: a clinical cohort study.</gtr:title><gtr:parentPublicationTitle>International journal of geriatric psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac5409df039f4b97af5db8674f4d55c7"><gtr:id>ac5409df039f4b97af5db8674f4d55c7</gtr:id><gtr:otherNames>Sultana J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0885-6230</gtr:issn><gtr:outcomeId>546660e94f54c7.17421463</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E833085-4514-4577-B47E-7277DA20D5EB</gtr:id><gtr:title>Reasons for discontinuing clozapine: A cohort study of patients commencing treatment.</gtr:title><gtr:parentPublicationTitle>Schizophrenia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b08236710891f8acdc5c57fac2408b5"><gtr:id>3b08236710891f8acdc5c57fac2408b5</gtr:id><gtr:otherNames>Legge SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0920-9964</gtr:issn><gtr:outcomeId>5aab9fe0bbd585.10996997</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D49CCC3F-5D09-48AC-9B07-4B3724163C8E</gtr:id><gtr:title>Negative symptoms in schizophrenia: a study in a large clinical sample of patients using a novel automated method.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10db95fd56b961dd90153cd3acb87a32"><gtr:id>10db95fd56b961dd90153cd3acb87a32</gtr:id><gtr:otherNames>Patel R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>561e0f8c041855.15448055</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>635C4134-FF98-46AF-A480-40BAAC53EDE2</gtr:id><gtr:title>Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process.</gtr:title><gtr:parentPublicationTitle>BMC psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2c455d3b31cbabfea46dcfa41268cdf"><gtr:id>a2c455d3b31cbabfea46dcfa41268cdf</gtr:id><gtr:otherNames>Kadra G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-244X</gtr:issn><gtr:outcomeId>561e091ac693f9.28563667</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73365E6C-522C-4E5D-8E7A-EC1A2CFC0604</gtr:id><gtr:title>Mini-mental state examination as a predictor of mortality among older people referred to secondary mental healthcare.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ee1a86502d5efaf58db5d0307f3a20d"><gtr:id>6ee1a86502d5efaf58db5d0307f3a20d</gtr:id><gtr:otherNames>Su YP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5466669db170f7.26747193</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21C8F620-842C-41A8-B92B-58A9EDFE6931</gtr:id><gtr:title>The impact of co-morbid personality disorder on use of psychiatric services and involuntary hospitalization in people with severe mental illness.</gtr:title><gtr:parentPublicationTitle>Social psychiatry and psychiatric epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85cfe5ef9bc17623ae1af3c27e37b1b7"><gtr:id>85cfe5ef9bc17623ae1af3c27e37b1b7</gtr:id><gtr:otherNames>Fok ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0933-7954</gtr:issn><gtr:outcomeId>5466619fcb4f98.43717280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4773C95A-0981-4426-9E30-22BC8519ED4F</gtr:id><gtr:title>A cohort study on mental disorders, stage of cancer at diagnosis and subsequent survival.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c812aa896949ebac06c11e24151b2860"><gtr:id>c812aa896949ebac06c11e24151b2860</gtr:id><gtr:otherNames>Chang CK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>54665ab46e5959.57808965</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DF6D201-B41B-4F42-994C-D008F454C36F</gtr:id><gtr:title>Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer's disease: a retrospective survival analysis.</gtr:title><gtr:parentPublicationTitle>Age and ageing</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aadee682043e41c5bbe23dd440cf3aa2"><gtr:id>aadee682043e41c5bbe23dd440cf3aa2</gtr:id><gtr:otherNames>Mueller C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0002-0729</gtr:issn><gtr:outcomeId>5aaba382d87b10.45245155</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8065FDCB-69AC-4743-8B3F-A2B557C76196</gtr:id><gtr:title>Clinical predictors of antipsychotic use in children and adolescents with autism spectrum disorders: a historical open cohort study using electronic health records.</gtr:title><gtr:parentPublicationTitle>European child &amp; adolescent psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb90a833dbe37ce12de107ab7a5f2964"><gtr:id>eb90a833dbe37ce12de107ab7a5f2964</gtr:id><gtr:otherNames>Downs J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1018-8827</gtr:issn><gtr:outcomeId>56afb856f00a27.40236531</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E39051E-68BE-4C7B-981C-1493C5A41115</gtr:id><gtr:title>Validation of the standardised assessment of personality--abbreviated scale in a general population sample.</gtr:title><gtr:parentPublicationTitle>Personality and mental health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85cfe5ef9bc17623ae1af3c27e37b1b7"><gtr:id>85cfe5ef9bc17623ae1af3c27e37b1b7</gtr:id><gtr:otherNames>Fok ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-8621</gtr:issn><gtr:outcomeId>561e0ff9068e26.39245490</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94778497-7860-47F1-A5C0-0F6F213F87D3</gtr:id><gtr:title>Associations between the schizophrenia susceptibility gene ZNF804A and clinical outcomes in psychosis.</gtr:title><gtr:parentPublicationTitle>Translational psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66f1a132b4eef82cbf2f7e481929b847"><gtr:id>66f1a132b4eef82cbf2f7e481929b847</gtr:id><gtr:otherNames>Wickramasinghe A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2158-3188</gtr:issn><gtr:outcomeId>56afbb708b21e9.14738155</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EDF293A-75E4-4392-BFB8-585FDF757721</gtr:id><gtr:title>Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6af8c165f402df2ac124cdc92216cae8"><gtr:id>6af8c165f402df2ac124cdc92216cae8</gtr:id><gtr:otherNames>Thompson JV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>56e7a0f728ce91.53493289</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2517659B-4F71-4400-9A77-66FC96F8D644</gtr:id><gtr:title>TextHunter--A User Friendly Tool for Extracting Generic Concepts from Free Text in Clinical Research.</gtr:title><gtr:parentPublicationTitle>AMIA ... Annual Symposium proceedings. AMIA Symposium</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c51a1386df2cc23690aa39ba482633fa"><gtr:id>c51a1386df2cc23690aa39ba482633fa</gtr:id><gtr:otherNames>Jackson MSc RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1559-4076</gtr:issn><gtr:outcomeId>56afbb713d71a2.42929657</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CEFF46B-980A-4347-99BB-94CE9EF40BBC</gtr:id><gtr:title>Comparisons of polydrug use at national and inner city levels in England: associations with demographic and socioeconomic factors.</gtr:title><gtr:parentPublicationTitle>Annals of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d479acd4ac799ba57c3a611e063957f"><gtr:id>4d479acd4ac799ba57c3a611e063957f</gtr:id><gtr:otherNames>Carter JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1047-2797</gtr:issn><gtr:outcomeId>pm_23439_29_23953948</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54C1CFBA-3930-4B9E-9139-B8A2A2187848</gtr:id><gtr:title>Predictors of care home and hospital admissions and their costs for older people with Alzheimer's disease: findings from a large London case register.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ced01270f523bbb21ee41a964fad5f9"><gtr:id>7ced01270f523bbb21ee41a964fad5f9</gtr:id><gtr:otherNames>Knapp M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>5aaba0a8810a45.75452584</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A90D777E-957D-4AE6-AC32-3ABB10D5A1D5</gtr:id><gtr:title>Linking health and education data to plan and evaluate services for children.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb90a833dbe37ce12de107ab7a5f2964"><gtr:id>eb90a833dbe37ce12de107ab7a5f2964</gtr:id><gtr:otherNames>Downs J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0003-9888</gtr:issn><gtr:outcomeId>5aaba14028ed96.28687884</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1B9DB13-A9E7-49A4-AF4B-C8C0594787B5</gtr:id><gtr:title>Cohort profile of the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Case Register: current status and recent enhancement of an Electronic Mental Health Record-derived data resource.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4dcc13bf4e47e8d345d9a4c258b4c7c9"><gtr:id>4dcc13bf4e47e8d345d9a4c258b4c7c9</gtr:id><gtr:otherNames>Perera G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>56e7a0f6eb8b34.57309033</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D9B5879-C38D-4D5B-B6E6-21F6D37C8C87</gtr:id><gtr:title>Predictors of natural and unnatural mortality among patients with personality disorder: evidence from a large UK case register.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85cfe5ef9bc17623ae1af3c27e37b1b7"><gtr:id>85cfe5ef9bc17623ae1af3c27e37b1b7</gtr:id><gtr:otherNames>Fok ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>546662901e4834.34076973</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56C571A0-8156-4FFC-A7E3-EEF463C0F80B</gtr:id><gtr:title>Antipsychotic polypharmacy prescribing and risk of hospital readmission.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2c455d3b31cbabfea46dcfa41268cdf"><gtr:id>a2c455d3b31cbabfea46dcfa41268cdf</gtr:id><gtr:otherNames>Kadra G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>5aaba3838e99c4.36745514</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DD14583-EF5E-4799-9F03-85EDF4C8BBBC</gtr:id><gtr:title>Suicide completion in secondary mental healthcare: a comparison study between schizophrenia spectrum disorders and all other diagnoses.</gtr:title><gtr:parentPublicationTitle>BMC psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89c4f6b5ffe37b7002c90021418bd576"><gtr:id>89c4f6b5ffe37b7002c90021418bd576</gtr:id><gtr:otherNames>Lopez-Morinigo JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-244X</gtr:issn><gtr:outcomeId>54666434e4aaa2.99321138</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D77279F-05F8-4E5F-96DE-898817A5E4A1</gtr:id><gtr:title>Personality disorder and self-rated health: a population-based cross-sectional survey.</gtr:title><gtr:parentPublicationTitle>Journal of personality disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0777c5254e4193281126a5e8db038de"><gtr:id>d0777c5254e4193281126a5e8db038de</gtr:id><gtr:otherNames>Fok M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0885-579X</gtr:issn><gtr:outcomeId>pm_23439_29_23795755</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67D37390-4374-4033-B6FA-01BD8FAE7AAB</gtr:id><gtr:title>The Association Between Comorbid Autism Spectrum Disorders and Antipsychotic Treatment Failure in Early-Onset Psychosis: A Historical Cohort Study Using Electronic Health Records.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c02740cd669ce4fdddb99a67b251842"><gtr:id>6c02740cd669ce4fdddb99a67b251842</gtr:id><gtr:otherNames>Downs JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0160-6689</gtr:issn><gtr:outcomeId>5aaba2b3a2ca17.46230390</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B3B5F21-7256-49A3-BBC2-87742A7564D4</gtr:id><gtr:title>Evaluation of smoking status identification using electronic health records and open-text information in a large mental health case register.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08f4de8e0f0faf8275e2e82a838b899e"><gtr:id>08f4de8e0f0faf8275e2e82a838b899e</gtr:id><gtr:otherNames>Wu CY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_23439_29_24069288</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>814C4175-FF7F-4AFD-B856-505A2F6FF764</gtr:id><gtr:title>Predictors of long-term (=6months) antipsychotic polypharmacy prescribing in secondary mental healthcare.</gtr:title><gtr:parentPublicationTitle>Schizophrenia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2c455d3b31cbabfea46dcfa41268cdf"><gtr:id>a2c455d3b31cbabfea46dcfa41268cdf</gtr:id><gtr:otherNames>Kadra G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0920-9964</gtr:issn><gtr:outcomeId>585d6e9d307183.37480246</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51344D47-5471-4EE8-93E1-BCA481739DC5</gtr:id><gtr:title>Double trouble: Psychiatric comorbidity and opioid addiction-all-cause and cause-specific mortality.</gtr:title><gtr:parentPublicationTitle>Drug and alcohol dependence</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fd22880a1f077463fb14f449cd18ae3"><gtr:id>7fd22880a1f077463fb14f449cd18ae3</gtr:id><gtr:otherNames>Bogdanowicz KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0376-8716</gtr:issn><gtr:outcomeId>561e08eb4eb7e0.13612159</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80BFEEF5-C5B1-408A-B522-864F6B8C4BC5</gtr:id><gtr:title>Contributions of specific causes of death to lost life expectancy in severe mental illness.</gtr:title><gtr:parentPublicationTitle>European psychiatry : the journal of the Association of European Psychiatrists</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8a6b2f892a1b9d5169ec4c9174f23fa"><gtr:id>c8a6b2f892a1b9d5169ec4c9174f23fa</gtr:id><gtr:otherNames>Jayatilleke N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0924-9338</gtr:issn><gtr:outcomeId>5a2fd73c0e6778.93490764</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AAD3905E-9F03-4328-9E72-AE8095BC2D4F</gtr:id><gtr:title>Identifying mortality risks in patients with opioid use disorder using brief screening assessment: Secondary mental health clinical records analysis.</gtr:title><gtr:parentPublicationTitle>Drug and alcohol dependence</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fd22880a1f077463fb14f449cd18ae3"><gtr:id>7fd22880a1f077463fb14f449cd18ae3</gtr:id><gtr:otherNames>Bogdanowicz KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0376-8716</gtr:issn><gtr:outcomeId>585d6e99a9aa42.43462681</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A234723-0910-4C75-8487-99417720E0BC</gtr:id><gtr:title>Excess overdose mortality immediately following transfer of patients and their care as well as after cessation of opioid substitution therapy.</gtr:title><gtr:parentPublicationTitle>Addiction (Abingdon, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fd22880a1f077463fb14f449cd18ae3"><gtr:id>7fd22880a1f077463fb14f449cd18ae3</gtr:id><gtr:otherNames>Bogdanowicz KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0965-2140</gtr:issn><gtr:outcomeId>5a679341bb8124.16495393</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AB4421D-C3EF-4301-BCE8-0340AAD62C83</gtr:id><gtr:title>Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome.</gtr:title><gtr:parentPublicationTitle>Acta psychiatrica Scandinavica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ee1a86502d5efaf58db5d0307f3a20d"><gtr:id>6ee1a86502d5efaf58db5d0307f3a20d</gtr:id><gtr:otherNames>Su YP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-690X</gtr:issn><gtr:outcomeId>54665fe190b1d7.16617019</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J01219X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>9A8BEDCC-D902-4C9A-8CCF-C974265EA3FB</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.4  Surveillance and distribution</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>E4AF608A-CDB6-4CE6-AA10-95B3E043E22F</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>8.1  Organisation and delivery of services</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>237CBF0D-6B87-46FD-A97B-E432D87D3FE6</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>8.2  Health and welfare economics</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>